ARTICLE | Finance
The dynamics of Dyne
How Atlas start-up Dyne plans to use nucleic acids to treat rare muscle diseases
April 3, 2019 10:30 AM UTC
Incubated by Atlas Venture and launched Wednesday with a $50 million series A round, Dyne Therapeutics Inc. is using its muscle-targeting platform to develop therapies for rare diseases, beginning with myotonic dystrophy type 1 (DM1).
As it develops its own pipeline, the company could also in parallel seek partnerships based on its platform, potentially in cardiac indications, Atlas' Jason Rhodes told BioCentury...